drugset / Trial / NCT06463340

Study of SGR-3515 In Participants With Advanced Solid Tumors.

NCT06463340 ↗

Phase 1 Recruiting 52 enrolled Schrödinger, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

Timeline

Start
2024-06-18
Primary completion
2026-10-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject SGR-3515 Unknown — Oral

Indications

No indication recorded.